Unicycive Therapeutics, Inc.
4300 El Camino Real
Suite 210
Los Altos, CA 94022
United States
650 351 4495
https://unicycive.com
版塊: Healthcare
行業: Biotechnology
全職員工: 14
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Shalabh K. Gupta M.D., MPA | Founder, Chairman, CEO & President | 1.1M | 無 | 1974 |
| Dr. Pramod Gupta Ph.D. | Executive Vice President of Pharmaceutical & Business Operations | 675k | 無 | 1960 |
| Mr. Douglas Jermasek M.B.A. | Executive Vice President of Corporate Strategy | 412.5k | 無 | 1962 |
| Mr. John W. Townsend CPA | Chief Financial Officer | 197.86k | 無 | 1962 |
描述
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
公司管治
截至 無 止，Unicycive Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
